EVOLUTION
13 Dec 2022
ANZUP2001
NCT05150236
Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC)
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Cancer Type | Prostate |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 Years and older |
Sex | Male |
Tumour Stream | - |
Cancer Stage | Metastatic or Widespread |
Anticipated Start Date | 2022-04-29 |
Anticipated End Date | 2024-12-01 |
Hospital | Royal Adelaide Hospital |
---|---|
Clinical Trial Coordinator | Anne Milton |
anne.milton@sa.gov.au | |
Phone | 08 7074 2342 |
Principal Investigator | Dr Hsiang Tan |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs